Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ongoing Phase III Study Could Provide Xinlay Back-Up Option, Abbott Says

Sep 12 2005

• By Mary Jo Laffler

Related Content

Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA

Jul 09 2004

Abbott Xinlay Lack Of Efficacy, CV Safety Will Be Likely Focus Of Advisory Cmte. Review

Sep 12 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window